| 汤伯宗,李曼,高月求.抑毒方治疗肝肾阴虚兼湿热型慢性乙型肝炎的疗效及对T细胞亚群的影响[J].,2010,30(8):823-827 |
| 抑毒方治疗肝肾阴虚兼湿热型慢性乙型肝炎的疗效及对T细胞亚群的影响 |
| Curative Effect of Yidu Recipe in Treating Chronic Hepatitis B Patients of Gan-Shen Yin-deficiency and Damp-Heat Syndrome Type and Its Influence of T-cell Subsets |
| |
| DOI： |
| 中文关键词: 乙型肝炎核心相关抗原 慢性乙型肝炎 自然杀伤T细胞 辅助T淋巴细胞 细胞毒T细胞 |
| 英文关键词:HBeAg chronic hepatitis B natural killer T-cell T-helper cell cytotoxic T-lymphocyte |
| 基金项目:国家传染病防治重大科技专项(No.2008ZX10005-006);上海市教育委员会E研究院建设计划项目(No.03008);上海市科学委员会引导项目(No.074119608);上海市浦东新区创新项目 |
|
| Hits: 1571 |
| Download times: 745 |
| 中文摘要: |
| 目的研究抑毒方治疗乙型肝炎核心相关抗原(hepatitis B e-antigen,HBeAg)阳性慢性乙型肝炎(chronic hepatitis B,CHB)患者的疗效及对T细胞亚群的数量及功能变化的影响。方法 57例HBeAg阳性CHB患者,根据治疗方案,随机分为单用恩替卡韦组(对照组)和恩替卡韦联合抑毒方组(治疗组)。治疗6个月后观察治疗前后ALT、AST、HBV-DNA、HBV-M、肝功能复常率、HBV-DNA转阴率、HBeAg转阴率、中医证候积分变化;应用流式细胞术检测HBeAg阳性CHB患者外周血中自然杀伤(NK)T细胞的数量和分泌γ-干扰素(IFN-γ)、白细胞介素-4(IL-4)的量,以及Th1、Th2、Tc1、Tc2细胞的数量。结果两组共有7例病例脱落。与对照组比较,治疗组能够明显降低ALT、AST、HBV-DNA水平及中医证候积分(P<0.05);并能明显提高肝功能复常率,而对HBV-DNA和HBeAg转阴率的提高,差异无统计学意义(P>0.05)。对照组能够明显增加NKT细胞分泌IFN-γ,减少分泌IL-4,增加Tc1细胞的数量,导致Tc1/Tc2比值升高,而治疗组不但可以增加NKT细胞的数量,使IFN-γ分泌增加,IL-4分泌减少,而且能够明显增加Th1、Tc1细胞数量,降低Th2、Tc2细胞数量,导致Th1/Th2、Tc1/Tc2的比值升高(P<0.05)。结论抑毒方能够有效改善HBeAg阳性CHB患者的肝功能、抑制HBV-DNA复制、改善临床症状;抑毒方的作用机制可能是通过增加NKT细胞的数量,使NKT细胞分泌IFN-γ增加,分泌IL-4降低,调节Th1/Th2与Tc1/Tc2之间的平衡而发挥作用。 |
| 英文摘要: |
| Objective To study the effect of Yidu Recipe(YDR) in treating patients of chronic hepatitis B(CHB) with positive hepatitis B e-antigen(HBeAg) and its influence on the quantity and function of T-cell subsets.Methods Fifty-seven CHB patients measured up the inclusive criteria were randomly assigned to the control group and the treated group,treated respectively by entecavir alone and entecavir + YDR for 6 months.Changes of alanine a minotransferase(ALT),aspartate a minotransferase(AST),HBV-DNA,HBV-M,interleukin-4(IL4) and Chinese medicine syndrome score,as well as amounts of natural killer(NK) T cell,γ-interferon(γIFN),Th1,Th2,Tc1 and Tc2 cells in peripheral blood(detected by flow cytometry) before and after treatment were observed.And the liver function normalization rate,negative inversion rates of HBV-DNA and HBeAg were estimated at terminal of the trial.Results Seven cases were dropped out in the observation period.Compared with the control group,levels of ALT,AST,HBV-DNA and Chinese medicine syndrome score were lower after treatment(P <0.05),and liver function normalization rate was higher in the treated group,while the difference between groups in negative inversion rates HBV-DNA and HBeAg were insignificant(P >0.05) .Amount of IFN-γ increased,IL-4 reduced,and Tc1 cell raised after treatment,which led to the rise of Tc1 /Tc2 ratio in both groups;while in the treated group,in addition to the above-mentioned changes,the Th1 cell was increased also,and thus to make elevation of Th1 /Th2 ratio(P <0.05) .Conclusion The efficacy of entecavir + YDR in treating HBeAg positive CHB patients is better than that of entecavir alone.YDR can effectively improve patients’ liver function,inhibit HBV-DNA replication and improve clinical symptoms,its action may be realized by way of increasing the amount of NKT cells,inducing increase of IFN-γ and decrease of IL-4 secretions,and regulating the balance between Th1 /Th2 and Tc1 /Tc2. |
| View Full Text View/Add Comment Download reader |
|
|
|
